| Autor: |
Membrillo de Novales FJ; CBRN and Infectious Diseases Department, Hospital Central de la Defensa 'Gómez Ulla', Spain.; Internal Medicine Department, Hospital La Moraleja, Madrid, Spain., Bravo de Pablo O; Internal Medicine Department, Hospital La Moraleja, Madrid, Spain., Estella Á; Intensive Care Department, University of Cádiz, Instituto de Investigación e Innovación Biomédica de Cádiz, Hospital Universitario de Jerez, Spain., Morata Ruiz L; Infectious Diseases Department, Hospital Clinic, Barcelona, Spain., Oltra Sempere MR; Infectious Diseases Unit, Hospital Clinic Universitari Valencia, Spain., Salavert Lleti M; Infectious Diseases Department, Hospital La Fe, Valencia, Spain., Estébanez Muñoz M; CBRN and Infectious Diseases Department, Hospital Central de la Defensa 'Gómez Ulla', Spain., Hidalgo-Tenorio C; Infectious Diseases Unit, Hospital Virgen de las Nieves, Granada, Spain. |
| Abstrakt: |
Competing Interests: Potential conflicts of interest. F. J. M. N. reports investigation grants from Advanz Pharma; payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from Advanz, Angelini, Correvio, MSD, Novartis, Pfizer, Gilead Sciences, ViiV Healthcare, and GSK; support for attending meetings and/or travel from Pfizer and MSD; and participation on advisory boards for Advanz and AstraZeneca. O. B. D. reports an investigation grant from Advanz. A. E. G. reports payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from Pfizer, Gilead Sciences, Advanz, MSD, Shionogi, and Menarini; and support for attending meetings and/or travel from Pfizer and Gilead Sciences. L. M. R. reports payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events for Pfizer, Advanz, Angelini, MSD, and Menarini; and support for attending meetings and/or travel from Pfizer and Angelini. M. R. O. S. reports payment or honoraria for presentations in educational events for Pfizer, MSD, Gilead Sciences, GSK and Menarini; support for attending a medical congress from Angelini; and participation in an advisory board for Advanz. M. S. L. reports payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from Advanz, Angelini, Gilead, Janssen, Menarini, MSD, Pfizer, Shionogi, and Takeda; and support for attending meetings and/or travel from Pfizer, Gilead, and Takeda. M. E. M. reports payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from from Advanz, Gilead Sciences, and ViiV. C. H.-T. reports payment for expert testimony from Gilead, Janssen, Angelini, Shionogi, MSD, ViiV, and Bristol-Myers Squibb (BMS); support for attending meetings and/or travel from Gilead, Janssen, Angelini, Shionogi, MSD, ViiV, and BMS; and participation on a data and safety monitoring board or advisory board for Gilead, Janssen, Advanz, Angelini, Shionogi, MSD, ViiV, and BMS. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. |
